ZA200506988B - Composition comprising iscom particles and live micro-organisms - Google Patents
Composition comprising iscom particles and live micro-organisms Download PDFInfo
- Publication number
- ZA200506988B ZA200506988B ZA200506988A ZA200506988A ZA200506988B ZA 200506988 B ZA200506988 B ZA 200506988B ZA 200506988 A ZA200506988 A ZA 200506988A ZA 200506988 A ZA200506988 A ZA 200506988A ZA 200506988 B ZA200506988 B ZA 200506988B
- Authority
- ZA
- South Africa
- Prior art keywords
- iscom
- micro
- vaccine
- composition
- live
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 239000002245 particle Substances 0.000 title claims abstract description 48
- 230000000890 antigenic effect Effects 0.000 claims abstract description 27
- 239000002671 adjuvant Substances 0.000 claims abstract description 26
- 229960005486 vaccine Drugs 0.000 claims description 86
- 239000000427 antigen Substances 0.000 claims description 39
- 102000036639 antigens Human genes 0.000 claims description 39
- 108091007433 antigens Proteins 0.000 claims description 39
- 239000011159 matrix material Substances 0.000 claims description 25
- 241000700605 Viruses Species 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 150000002338 glycosides Chemical class 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 229930182470 glycoside Natural products 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 14
- 230000003362 replicative effect Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 150000007949 saponins Chemical class 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 229930182490 saponin Natural products 0.000 description 8
- 235000017709 saponins Nutrition 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- 230000002238 attenuated effect Effects 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 241000282326 Felis catus Species 0.000 description 5
- 235000009001 Quillaja saponaria Nutrition 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 4
- 241000282324 Felis Species 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 241000714165 Feline leukemia virus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001092142 Molina Species 0.000 description 3
- 241001454523 Quillaja saponaria Species 0.000 description 3
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241001647378 Chlamydia psittaci Species 0.000 description 2
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 description 2
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 description 2
- 241000714201 Feline calicivirus Species 0.000 description 2
- 108010015899 Glycopeptides Proteins 0.000 description 2
- 102000002068 Glycopeptides Human genes 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010028921 Lipopeptides Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 241001092473 Quillaja Species 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 229940124861 Rabies virus vaccine Drugs 0.000 description 2
- 102400000368 Surface protein Human genes 0.000 description 2
- 101800001271 Surface protein Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 229940124590 live attenuated vaccine Drugs 0.000 description 2
- 229940023012 live-attenuated vaccine Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- PIGTXFOGKFOFTO-FVFWYJKVSA-N (2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-carboxy-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)C[C@@H](O)[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O PIGTXFOGKFOFTO-FVFWYJKVSA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- WQTCTMDKQPZJES-UHFFFAOYSA-N 2-aminoethyl dihydrogen phosphate;nonane Chemical compound NCCOP(O)(O)=O.CCCCCCCCC.CCCCCCCCC WQTCTMDKQPZJES-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 1
- 208000010884 Bursa disease Diseases 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 241000701157 Canine mastadenovirus A Species 0.000 description 1
- 241000712083 Canine morbillivirus Species 0.000 description 1
- 241000701931 Canine parvovirus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000002613 Feline Panleukopenia Diseases 0.000 description 1
- 241000701915 Feline panleukopenia virus Species 0.000 description 1
- 241000701925 Feline parvovirus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 229940124841 Herpesvirus vaccine Drugs 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241001550390 Leptospira interrogans serovar Canicola Species 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000006758 Marek Disease Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 description 1
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 241000702619 Porcine parvovirus Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000219287 Saponaria Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- -1 carrier Substances 0.000 description 1
- 229940032077 cervical cancer vaccine Drugs 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000249 enterotoxic Toxicity 0.000 description 1
- 230000002242 enterotoxic effect Effects 0.000 description 1
- 108010043839 feline leukemia virus vaccine Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
- 229910001679 gibbsite Inorganic materials 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002766 immunoenhancing effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0300795A SE0300795D0 (sv) | 2003-03-24 | 2003-03-24 | Composition comprising iscom particles and live micro-organisms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200506988B true ZA200506988B (en) | 2006-07-26 |
Family
ID=20290755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200506988A ZA200506988B (en) | 2003-03-24 | 2005-08-31 | Composition comprising iscom particles and live micro-organisms |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US7838019B2 (sv) |
| EP (1) | EP1635867B1 (sv) |
| AT (1) | ATE544471T1 (sv) |
| AU (1) | AU2004224487B2 (sv) |
| BR (1) | BRPI0408587A (sv) |
| CA (1) | CA2519806C (sv) |
| ES (1) | ES2379351T3 (sv) |
| NZ (1) | NZ542328A (sv) |
| SE (1) | SE0300795D0 (sv) |
| WO (1) | WO2004084941A1 (sv) |
| ZA (1) | ZA200506988B (sv) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0300795D0 (sv) | 2003-03-24 | 2003-03-24 | Isconova Ab | Composition comprising iscom particles and live micro-organisms |
| PL1838341T3 (pl) | 2005-01-20 | 2014-04-30 | Isconova Ab | Kompozycja szczepionki obejmująca białko wiążące fibronektynę lub peptyd wiążący fibronektynę |
| US7682619B2 (en) | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
| AU2010269148A1 (en) * | 2009-07-10 | 2012-01-19 | Isconova Ab | New composition |
| GB201016471D0 (en) * | 2010-09-30 | 2010-11-17 | Isis Innovation | Viral vector immunogenic compositions |
| CA2922258C (en) | 2013-09-19 | 2022-11-29 | Novavax, Inc. | Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods |
| EP3118216A1 (en) | 2015-07-16 | 2017-01-18 | Nuritas Limited | Cellular growth and proliferation promoting peptides, and uses thereof |
| EP3117830A1 (en) | 2015-07-16 | 2017-01-18 | Nuritas Limited | Antibacterial peptides, and uses thereof |
| EP3117831A1 (en) | 2015-07-16 | 2017-01-18 | Nuritas Limited | Peptides for use in promoting transport of glucose into skeletal muscle |
| BR112018000660A2 (pt) | 2015-07-16 | 2019-05-14 | Nuritas Limited | peptídeos anti-inflamatórios e seu uso |
| EP3118215A1 (en) | 2015-07-16 | 2017-01-18 | Nuritas Limited | Anti-inflammatory peptides, and uses thereof |
| WO2018014936A1 (en) | 2016-07-18 | 2018-01-25 | Nuritas Limited | Topical compositions |
| WO2018104346A1 (en) | 2016-12-05 | 2018-06-14 | Nuritas Limited | Compositions comprising peptide wkdeagkplvk |
| EP3329905A1 (en) | 2016-12-05 | 2018-06-06 | Nuritas Limited | Topical cosmetic compositions comprising an oligopeptide against anti-aging of the skin |
| WO2019238962A1 (en) | 2018-06-14 | 2019-12-19 | University College Cork - National University Of Ireland, Cork | Peptide for disease treatment |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0231039B1 (en) * | 1986-01-14 | 1992-01-08 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Process for preparing immunological complexes and pharmaceutical composition containing these complexes |
| NZ230747A (en) * | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| GB8919819D0 (en) | 1989-09-01 | 1989-10-18 | Coopers Animal Health | Complexes having adjuvant activity |
| NL9002314A (nl) | 1990-10-23 | 1992-05-18 | Nederlanden Staat | Immunogene complexen, in het bijzonder iscoms. |
| GB9320668D0 (en) * | 1993-10-07 | 1993-11-24 | Secr Defence | Liposomes containing particulare materials |
| CA2185097A1 (en) * | 1994-03-09 | 1995-09-14 | Stephen R. Wechter | Activating virus |
| AUPM873294A0 (en) * | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US5676354A (en) * | 1995-07-14 | 1997-10-14 | Fuji Photo Film Co., Ltd. | Sheet film pack |
| US5753235A (en) * | 1996-02-15 | 1998-05-19 | Heska Corporation | Recombinant canine herpesviruses |
| ATE199022T1 (de) * | 1996-10-09 | 2001-02-15 | Akzo Nobel Nv | Europäische vakzinstämme des fortplanzungs- atmungs-syndromsvirus des sweins (prrsv) |
| DE60330257D1 (de) | 2002-10-02 | 2010-01-07 | Nordic Vaccine Technology As | Zusammensetzung zur impfung |
| SE0300795D0 (sv) | 2003-03-24 | 2003-03-24 | Isconova Ab | Composition comprising iscom particles and live micro-organisms |
-
2003
- 2003-03-24 SE SE0300795A patent/SE0300795D0/sv unknown
-
2004
- 2004-03-24 WO PCT/SE2004/000451 patent/WO2004084941A1/en active Application Filing
- 2004-03-24 US US10/550,026 patent/US7838019B2/en active Active
- 2004-03-24 AT AT04723123T patent/ATE544471T1/de active
- 2004-03-24 AU AU2004224487A patent/AU2004224487B2/en not_active Expired
- 2004-03-24 CA CA2519806A patent/CA2519806C/en not_active Expired - Lifetime
- 2004-03-24 ES ES04723123T patent/ES2379351T3/es not_active Expired - Lifetime
- 2004-03-24 BR BRPI0408587-6A patent/BRPI0408587A/pt not_active Application Discontinuation
- 2004-03-24 NZ NZ542328A patent/NZ542328A/xx unknown
- 2004-03-24 EP EP04723123A patent/EP1635867B1/en not_active Revoked
-
2005
- 2005-08-31 ZA ZA200506988A patent/ZA200506988B/en unknown
-
2010
- 2010-10-15 US US12/905,418 patent/US20110081378A1/en not_active Abandoned
-
2014
- 2014-01-02 US US14/146,365 patent/US9205147B2/en not_active Expired - Lifetime
-
2015
- 2015-11-05 US US14/933,722 patent/US9901634B2/en not_active Expired - Lifetime
-
2018
- 2018-01-22 US US15/876,630 patent/US10813994B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20080095795A1 (en) | 2008-04-24 |
| CA2519806C (en) | 2012-06-19 |
| US20160114034A1 (en) | 2016-04-28 |
| BRPI0408587A (pt) | 2006-03-21 |
| US9205147B2 (en) | 2015-12-08 |
| US9901634B2 (en) | 2018-02-27 |
| AU2004224487A1 (en) | 2004-10-07 |
| US20110081378A1 (en) | 2011-04-07 |
| US20140120131A1 (en) | 2014-05-01 |
| EP1635867B1 (en) | 2012-02-08 |
| WO2004084941A1 (en) | 2004-10-07 |
| AU2004224487B2 (en) | 2009-08-06 |
| ES2379351T3 (es) | 2012-04-25 |
| NZ542328A (en) | 2009-10-30 |
| EP1635867A1 (en) | 2006-03-22 |
| US7838019B2 (en) | 2010-11-23 |
| ATE544471T1 (de) | 2012-02-15 |
| US10813994B2 (en) | 2020-10-27 |
| US20200323979A9 (en) | 2020-10-15 |
| SE0300795D0 (sv) | 2003-03-24 |
| US20180369369A1 (en) | 2018-12-27 |
| CA2519806A1 (en) | 2004-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10813994B2 (en) | Composition comprising iscom particles and live micro-organisms | |
| US20200215189A1 (en) | Iscom preparation and use thereof | |
| KR100720213B1 (ko) | 미세 유동화된 수중 유적형 유화액 및 백신 조성물 | |
| EP1742659B1 (en) | Microfluidized oil-in-water emulsions and vaccine compositions | |
| CA2064911A1 (en) | Adjuvant complexes |